ReportWire

Tag: pharmaceutical industry

  • More than 4.5 million fentanyl pills, 3,000 pounds of methamphetamine seized in Arizona investigation, DEA says | CNN

    More than 4.5 million fentanyl pills, 3,000 pounds of methamphetamine seized in Arizona investigation, DEA says | CNN

    [ad_1]



    CNN
     — 

    Arizona authorities targeting the Sinaloa drug cartel have seized narcotics estimated to be worth more than $13 million, including more than 4.5 million fentanyl pills, 3,100 pounds of methamphetamine and large quantities of heroin, cocaine and fentanyl powder, according to the Drug Enforcement Administration.

    In a news release, the agency said the seizure was the culmination of a three-year-long investigation during which 150 people had so far been charged.

    “The fentanyl seized represents more than 30 million potentially lethal doses,” the DEA said, announcing the seizure in partnership with the Tempe Police Department and Arizona Attorney General Kris Mayes.

    Authorities displayed some of the recovered narcotics at a joint news conference Thursday, attended by CNN affiliate KNXV.

    “The sample you see here today is staggering. There are over 4.5 million fentanyl pills, over 140 pounds of fentanyl powder, over 135 kilos of cocaine, over 3,000 pounds of methamphetamine, 35 kilos of heroin, 49 firearms and over $2 million in cash,” Interim Tempe Police Chief Josie Montenegro told reporters.

    Montenegro said the substances recovered “would be poisoning members of our community, including our youth and vulnerable population,” had the seizures not been made.

    “In addition, the dangers and crimes associated with illegal drugs would be plaguing our community,” Montenegro added.

    According to authorities, “numerous” people were taken into custody in the bust. At this time, authorities do not plan on releasing the names of those involved because it is a continuing investigation, according to Montenegro.

    Phoenix DEA Special Agent in Charge Cheri Oz said investigators are “laser-focused” on the Sinaloa cartel.

    “I want to be crystal clear, the drugs in this room and the drugs that are flooding Arizona every single day are sourced primarily by one evil as the Sinaloa drug cartel,” she said at the news conference. “We are laser-focused on the Sinaloa drug cartel and we will defeat them. We will not stop.”

    Oz also praised the efforts of DEA agents and other officers over the last three years. “Their hard work and tenacity is responsible for removing these deadly drugs before they poisoned our family, our friends and our neighborhoods,” she said.

    The country is struggling with a decades-long opioid epidemic in which fentanyl has become the most commonly used drug involved in overdoses.

    Pharmaceutical fentanyl is a synthetic opioid intended to help patients manage severe pain. It is 50 to 100 times more potent than morphine, and typically prescribed in the form of skin patches or lozenges. But most recent cases of fentanyl-related harm, overdose, and death in the United States are linked to illegally made fentanyl, according to the US Centers for Disease Control and Prevention.

    Deaths involving synthetic opioids increased by 22% in 2021, according to CDC data, and in 2022, there were about 181,806 nonfatal opioid overdoses recorded in the United States.

    [ad_2]

    Source link

  • 12 blue states sue FDA, saying it’s too strict in limiting abortion drugs as legal battle over mifepristone heats up | CNN Politics

    12 blue states sue FDA, saying it’s too strict in limiting abortion drugs as legal battle over mifepristone heats up | CNN Politics

    [ad_1]



    CNN
     — 

    Twelve states led by liberal attorneys general announced Friday that they had sued the Food and Drug Administration, saying its limits on mifepristone, one of the two drugs used for medication abortion, are too strict.

    The suit is a possible hedge by states waiting to see how a federal judge in Texas rules in a lawsuit brought by anti-abortion groups seeking to block the FDA’s approval of mifepristone altogether. Conflicting rulings could mean the Supreme Court is asked to sort out the issue.

    RELATED: How a medication abortion, also known as an ‘abortion pill,’ works

    “The federal government has known for years that mifepristone is safe and effective,” Washington state Attorney General Bob Ferguson said in a statement. “In the wake of the Supreme Court’s radical decision overturning Roe v. Wade, the FDA is now exposing doctors, pharmacists and patients to unnecessary risk. The FDA’s excessive restrictions on this important drug have no basis in medical science.”

    Mifepristone was first approved in 2000 and medication abortion accounts for more than half of the abortions in the US. It is the first drug, followed by misoprostol, in the medication abortion regimen. Patients and providers must sign agreements stating the drug will be used to end a pregnancy, and pharmacies must have special certification.

    The lawsuit was filed in federal court in the Eastern District of Washington state. The states in the lawsuit are: Washington, Oregon, Arizona, Colorado, Connecticut, Delaware, Illinois, Michigan, Nevada, New Mexico, Rhode Island and Vermont.

    A lawsuit seeking to block the use of medication abortion nationwide could receive an initial decision at any moment, after the plaintiffs in the case submitted to the court on Friday their final brief on the challenge.

    The lawsuit, filed in November by anti-abortion advocates against FDA, challenges the two-decade-old approval of mifepristone, the first drug in the medication abortion process.

    A decision by US District Judge Matthew Kacsmaryk, an appointee of former President Donald Trump, in favor of the plaintiffs could have far-reaching consequences since medication abortion now makes up a majority of abortions obtained in the US.

    In the filing submitted Friday, the anti-abortion advocates rehashed many of the arguments they made in earlier briefs. Its submission means that Kacsmaryk could soon rule on a motion by the plaintiffs to temporarily block use of the medication. The judge had previously said that once the February 24 filing deadline ended, “briefing will then be closed on the matter, absent any ‘exceptional or extraordinary circumstances.’”

    Kacsmaryk, however, could also call for a hearing, or ask for additional responses.

    The defendants in the case – the FDA and Danco, which makes mifepristone – argued in separate briefs to the court that a decision against the drug’s approval would be unprecedented and would shutter the drugmaker’s business.

    Reproductive rights advocates have stressed that a ruling in favor of the plaintiffs would be devastating, with NARAL Pro-Choice America saying in a statement that if the drug is yanked from the market, “64.5 million women of reproductive age in the US would lose access to medication abortion care, an exponential increase in harm overnight.”

    [ad_2]

    Source link

  • After recent student fentanyl overdoses in Texas community, court documents reveal drug supplier lived blocks away from schools | CNN

    After recent student fentanyl overdoses in Texas community, court documents reveal drug supplier lived blocks away from schools | CNN

    [ad_1]



    CNN
     — 

    Parents across the Carrollton-Farmers Branch Independent School District (CFBISD), located in a Dallas, Texas, suburb, are reeling following a string fentanyl overdoses by nine students who attend schools in the district.

    The students, who range in age from 13 to 17 and are not identified by name in court documents, overdosed between September 18, 2022 and February 1, 2023. Three of the students died, and one of the students, a 14-year-old girl, overdosed twice, according to a statement by the US Attorney’s Office, Northern District of Texas.

    Law enforcement officers traced the drugs the students overdosed on to a house within walking distance from a middle school and a high school, court documents say.

    “First with all the school shootings, now this with drugs,” Lupe Rebadan, who has two children, as well as nieces and nephews, attending schools in the district told CNN. “Our kids are not safe at school… When is this all going to stop?”

    Luis Eduardo Navarette and Magaly Mejia Cano have been charged with conspiracy to distribute fentanyl, according to the US Attorney’s Office.

    “To deal fentanyl is to knowingly imperil lives. To deal fentanyl to minors – naive middle and high school students – is to shatter futures. These defendants’ alleged actions are simply despicable,” US Attorney Leigha Simonton said in the statement.

    The complaint illuminates a network of drug dealers and users, most of them teenagers who attend R.L. Turner High School, Dan Long Middle School and Dewitt Perry Middle School, and traced the proliferation of fentanyl tainted “M30” pills to Navarette and Cano’s residence.

    International drug trafficking organizations often produce M30 pills by mixing highly addictive fentanyl with acetaminophen “and other binder type substances and pressed into various tablets/pills,” says an affidavit by a Drug Enforcement Administration task force officer included in the criminal complaint.

    Many fake pills are made to look like prescription opioids such as oxycodone (Oxycontin, Percocet), hydrocodone (Vicodin), and alprazolam (Xanax); or stimulants like amphetamines (Adderall),” according to the DEA’s “One Pill Can Kill” website.

    Criminal organizations, according to the DEA officer’s affidavit, sell M30 pills for $1 to $2 dollars per pill when the purchasers buy in bulk amounts. Those are later sold to “street level dealers” for $3 to $5 per pill, and later sold to consumers for $10 per pill.

    Law enforcement tracked multiple teenagers engaging in “hand-to-hand transactions” with Navarette and Cano outside of their house, which is approximately five blocks from R.L. Turner High School and two blocks from DeWitt Perry Middle School, the court documents reveal.

    On January 12, a Carrollton Street Crimes Unit detective observed a 16-year-old obtain M30 pills from Navarette and Cano’s residence.

    The teenager appeared to crush and snort a pill on their front porch, “possibly package” the drugs, then walk toward the high school, where he was enrolled, according to the complaint.

    The school was notified by law enforcement, and later that day a school resource officer located the teenager in a bathroom making a “snorting sound” and appearing intoxicated.

    Navarette and Cano made their initial appearances in court on Monday, Erin Dooley of the US Attorney’s Office in Northern Texas told CNN. Naverette waived his right to a detention hearing and was ordered detained pending trial, and Cano had her detention hearing on Friday, she added. Attorneys for Navarette and Cano haven’t responded to CNN’s requests for comment.

    Days after the complaint outlining the 10 overdoses became available to the public, CFBISD released a statement expressing sorrow and concern over “the loss of young lives.”

    The district explained how it has educated the community about the threat from fentanyl over the past several months.

    “We will continue to work cooperatively with local law enforcement agencies to address this issue and to maximize safety on our campuses in every way possible. We believe if we work together as a community, we can avoid these tragedies,” the district said.

    The district said Narcan, or naloxone, an emergency drug used to treat fentanyl overdoses, had been obtained for all district facilities in October and random canine searches were being conducted on secondary campuses.

    Drug awareness presentations for parents will also resume this year, according to the district.

    “The fentanyl crisis is claiming far too many young Texans,” Texas Governor Greg Abbott tweeted Wednesday. Abbott launched the #OnePillKills campaign in October 2022 to “combat the growing national fentanyl crisis plaguing Texas.”

    In the first week of school in 2022, four students died from “fentanyl poisoning, or suspected poisoning” in Hays County Independent School District (HCISD), located in a suburb of Austin. This prompted the district to create “Fighting Fentanyl,” an informational campaign warning students and faculty about the deadly drug.

    Tim Savoy, the chief communication officer at HCISD, noted that the district has spent tens of millions of dollars for preventative measures against school shootings and Covid-19, two issues that have affected schools nationwide. The fentanyl crisis on school campuses deserves the same level of concern and response, he said.

    “This is a threat. We’re losing students, too. And so we made the decision that we have to get this equal attention and resources and do what we can,” Savoy told CNN.

    Despite the district’s awareness-raising campaign, an email from the superintendent on January 9 informed parents of “three more suspected accidental fentanyl poisonings” and one death in which fentanyl may have been to blame.

    “Our students are dying from this, and we have to do what we can,” Savoy said. “This is not just something that you’re seeing elsewhere. This is really happening in our community.”

    According to the Centers for Disease Control and Prevention, median monthly overdose deaths among 10- to 19-year-olds across the United States involving illicitly manufactured fentanyl surged 182% from December 2019 to December 2021.

    Adolescents are particularly vulnerable to fentanyl exposure due to the “proliferation of counterfeit pills resembling prescription drugs containing IMFs (illicitly manufactured fentanyls), and the ease of purchasing pills through social media,” according to the CDC.

    [ad_2]

    Source link

  • What to know about the lawsuit aiming to ban medication abortion drug mifepristone | CNN Politics

    What to know about the lawsuit aiming to ban medication abortion drug mifepristone | CNN Politics

    [ad_1]



    CNN
     — 

    A federal judge may rule later this month on a lawsuit seeking to block the use of medication abortion nationwide, in the biggest abortion-related case since the Supreme Court overturned Roe v. Wade last year.

    The lawsuit, filed in November by anti-abortion advocates against the US Food and Drug Administration, targets the agency’s 20-year-old approval of mifepristone, the first drug in the medication abortion process

    Medication abortion, which now makes up a majority of abortions obtained in the US, has become a particularly acute flashpoint in the fallout from the Supreme Court’s decision last year overturning Roe v. Wade.

    US District Judge Matthew Kacsmaryk, an appointee of former President Donald Trump, has extended the briefing deadline in the case until February 24.

    Reproductive rights advocates say that if Kacsmaryk sides with the plaintiffs, “it would eliminate the most commonly used method of abortion care,” according to NARAL Pro-Choice America.

    Here’s what to know about the lawsuit:

    The lawsuit, filed last year by a coalition of anti-abortion national medical associations under the umbrella of the “Alliance for Hippocratic Medicine” and several doctors, is seeking a number of actions by the court, chief among them a preliminary and permanent injunction ordering the FDA “to withdraw mifepristone and misoprostol as FDA-approved chemical abortion drugs and to withdraw defendants’ actions to deregulate these chemical abortion drugs.”

    “After two decades of engaging the FDA to no avail, plaintiffs now ask this court to do what the FDA was and is legally required to do: protect women and girls by holding unlawful, setting aside, and vacating the FDA’s actions to approve chemical abortion drugs and eviscerate crucial safeguards for those who undergo this dangerous drug regimen,” the complaint reads.

    The FDA responded to the lawsuit last month by asking the judge to deny the motion for a preliminary injunction, arguing that issuing one in the matter “would upend the status quo and the reliance interests of patients and doctors who depend on mifepristone, as well as businesses involved with mifepristone distribution.”

    The agency also says a ruling against it would set a dangerous precedent.

    “More generally, if longstanding FDA drug approvals were so easily enjoined, even decades after being issued, pharmaceutical companies would be unable to confidently rely on FDA approval decisions to develop the pharmaceutical-drug infrastructure that Americans depend on to treat a variety of health conditions,” the FDA wrote.

    “A preliminary injunction would interfere with Congress’s decision to entrust FDA with responsibility to ensure the safety and efficacy of drugs. In discharging this role, FDA applies its technical expertise to make complex scientific determinations about drugs’ safety and efficacy, and these determinations are entitled to substantial deference.”

    Danco, which makes mifepristone, also made a similar request to the FDA’s in a court filing, stressing that the lawsuit could decimate the company’s business.

    “Danco is a small pharmaceutical company. It sells one drug: Mifeprex,” lawyers for the company wrote in court papers. “Entering the mandatory preliminary injunction plaintiffs seek would force FDA to withdraw approval for Danco’s only product, effectively shuttering Danco’s business.”

    “Congress entrusts decision-making like this with the FDA. And they’re coming in trying to overrule that, saying this medication is unsafe because women bleed. Well, that’s part of having an abortion. It’s also part of having a pregnancy,” said Ryan Brown, an attorney representing Danco in the case. “The bottom line being that they just want to do away with abortion across the board and for any reason.”

    Kacsmaryk was appointed to the court in 2017 by then-President Trump and was confirmed by a 52-46 vote in 2019.

    Since then, he’s helped make Texas a legal graveyard for policies of President Joe Biden’s administration, presiding over 95% of the civil cases brought in Amarillo, Texas.

    In December, Kacsmaryk put on hold the Biden administration’s most recent attempt to end the so-called “Remain in Mexico” program. And he has overseen Texas cases challenging vaccine mandates, the gender identity guidance issued by the US Equal Employment Opportunity Commission and the administration’s limits on the use of Covid-19 relief funds for tax cuts.

    Before joining the court, Kacsmaryk served as deputy general counsel at the First Liberty Institute, a nonprofit religious liberty legal group, where he worked mainly on “religious liberty litigation in federal courts and amicus briefs in the US Supreme Court,” according to his White House biography.

    The case is being closely watched by a number of interested parties, including Republican and Democratic state attorneys general. On Friday, two different multi-state coalitions filed amicus briefs with the court urging them to act one way or another in the matter.

    A coalition of 22 Democratic attorneys general urged Kacsmaryk to deny the motion for a preliminary injunction, writing in court papers that “annulling – or even merely limiting – any of the FDA’s actions relating to medication abortion would result in an even more drastic reduction in abortion access across the entire nation, worsening already dire outcomes, deepening entrenched disparities in access to health care, and placing a potentially unbearable strain on the health care system as a whole.”

    And a coalition of 22 Republican attorneys general asked the court to issue the preliminary injunction, arguing the FDA exceeded its authority when it approved the medication.

    “State laws on chemical abortion thus account for the public interests at issue – and they do so with the benefit of democratic legitimacy (and legal authority). The FDA’s actions can make no such claim. By obstructing the judgments of elected representatives, the agency has undermined the public interest,” they wrote.

    Abortion rights advocates have sounded the alarm on the case, stressing that a ruling by Kacsmaryk in favor of the plaintiffs would affect every corner of the country since the lawsuit is targeting a federal agency.

    “If FDA approval of mifepristone is revoked, 64.5 million women of reproductive age in the US would lose access to medication abortion care, an exponential increase in harm overnight,” NARAL said in a statement on Friday, pointing to internal research.

    “This research reveals the high stakes of this lawsuit, and we can only expect the worst from this Trump-appointed federal judge. Americans want access to abortion, but anti-choice bad actors are dead set on restricting reproductive freedom by any means possible,” said Angela Vasquez-Giroux, the group’s vice president of communications and research.

    And activists are mobilizing in Texas around the issue, with the Women’s March planning to hold a rally at the federal courthouse in Amarillo, Texas, on Saturday.

    “We’ve said it before: the fight for reproductive rights now lies in the states, and legal challenges like these are just the latest example of how our fight is bigger than Roe,” said Rachel Carmona, the executive director of Women’s March.

    On Thursday, Kacsmaryk told the plaintiffs that they had until February 24 to respond to a recent filing by the Danco, writing in an order that following the deadline, “briefing will then be closed on the matter, absent any ‘exceptional or extraordinary circumstances.’”

    On Friday, the plaintiffs in the case submitted one response to the FDA’s filing. But the deadline extension means that after the plaintiffs submit a separate response to Danco, the case is ripe for judgment since all required briefings will have been filed.

    Kacsmaryk can rule at any time after that, though he could also call for a hearing, or ask for additional responses as well.

    [ad_2]

    Source link

  • Tracking the opioid crisis: Inside the DEA’s secret lab | CNN

    Tracking the opioid crisis: Inside the DEA’s secret lab | CNN

    [ad_1]

    Watch CNN Films’ “American Pain” at 9 p.m. ET Sunday, February 5.



    CNN
     — 

    Sitting among the warehouses of Dulles, Virginia, is one of the US Drug Enforcement Administration’s forensic labs. It’s one of eight across the country where scientists analyze illegal drugs and try to stay ahead of what’s driving deadly overdoses.

    Starting in the late 1990s with overprescribing of prescription narcotics, the opioid epidemic has continued to plague the United States for decades. What has changed is the type of drugs that have killed more than half a million people during the past 20 years.

    CNN was granted rare access to the secret lab where the DEA tests seized illicit drugs to understand what’s coming next.

    “The market is constantly changing, so we are trying to do everything we can from a science base to keep up with that,” Scott Oulton, deputy assistant administrator of the DEA’s Office of Forensic Sciences, told CNN Chief Medical Correspondent Dr. Sanjay Gupta.

    Holding a white bag of fentanyl precursor powder – one of the chemicals used to make the opioid – Oulton explained that the illicitly made painkiller continues to be a dominant presence in the drugs officials are finding.

    “This kilogram can be converted into fentanyl to make approximately 800 grams,” he said. “So it doesn’t take that much material, it’s fairly cheap, it’s inexpensive to obtain.”

    Fentanyl is the deadliest drug in the United States, and it’s often found in combination with other illicit drugs, including cocaine and heroin. But increasingly, fentanyl is showing up in illicit pills disguised as common prescription drugs like oxycodone, hydrocodone, even Adderall.

    Users buying drugs on the street that look like prescription pills may end up with a highly potent, potentially deadly drug they never intended to take.

    “Over 99% of what we see are fake. They contain fentanyl,” Oulton says of the pills that the agency is seizing.

    The 800 grams of fentanyl that Oulton held could be turned into 400,000 to 500,000 potentially lethal pills.

    As more and more of these lethal pills circulate, the opioid epidemic is reaching more of the population.

    Deena Loudon of Olney, Maryland, is among those living with its effects.

    “I truly love sharing Matthew with the world,” Loudon says as she flips through pictures of her son.

    One of her favorite memories is Matthew playing hockey – what Loudon calls his happy place.

    Matthew Loudon's mom says he turned to drugs after struggling with anxiety.

    But she also recalls his struggles with anxiety, which led him to turn to drugs. He started dabbling in them in the 10th grade. By the following year, his grades began to fall, and he couldn’t keep them high enough to stay in hockey.

    “He was using Xanax to help self-medicate himself and I think to help get rid of some of that angst so he could live somewhat of a normal life,” Loudon said.

    Matthew was always honest, almost to a fault, Loudon says. “He told me he tried everything. Like everything. Heroin, meth, crack, you name it, cocaine, whatever – until I guess he found what made him feel the best, and it was Xanax.”

    And as much as a mother can worry, Loudon says, Matthew always tried to reassure her. “I know what I’m doing,” he would tell her.

    She had heard about fentanyl showing up in pills in their area.

    “But you don’t ever think it’s going to happen to you,” Loudon said.

    She said they even had a conversation about fentanyl the day before he died. “I was sort of naive, wanting to stick my head in the sand and thinking ‘I bet he does know what he’s doing.’ ”

    On November 3, 2020, she found 21-year-old Matthew on the floor of their basement.

    Matthew’s autopsy report lists his cause of death as fentanyl and despropionyl fentanyl intoxication.

    “I don’t say he overdosed. I say he died from fentanyl poisoning. … Truthfully, like, at the end of the day, to me, he was murdered, right? Because he asked for one thing. They gave him something different. And it took his life.”

    For a parent, she said, the hardest thing is burying their child. It’s a pain she speaks out about in hopes of keeping other families safe.

    “It’s Russian roulette,” she warns them. “You never know what you’re gonna get.”

    The number of pills the DEA has seized skyrocketed in just three years, from 2.2 million in 2019 to 50.6 million in 2022.

    The sheer volume of pills has been one of the biggest challenges for the DEA’s lab, Oulton says. As the fentanyl threat continues to grow, the Virginia facility is expanding to accommodate the analysis needed.

    The lab can test for something as simple as the presence of fentanyl, but something called the purity of the pill also offers important insight. This means how much fentanyl is actually in one of these illicit pills.

    “Lately, we’ve been seeing a purity increase over the last year, where we used to say roughly four out of the 10 seizures that we were receiving would contain a lethal dose of greater than 2 milligrams. As of October last year, we started reporting that we’ve seen an uptick. Now we’re saying that six out of 10 of the seizures that we’re receiving contain over 2 milligrams,” Oulton said.

    He says they’re finding an average of 2.3 milligrams of fentanyl in each pill.

    Two milligrams may be the cutoff for what is considered lethal, but Oulton says that doesn’t necessarily mean a pill with 1.99 milligrams of fentanyl can’t be deadly.

    “One pill can kill” is his warning.

    “The message I would like to send out is, don’t take it,” he said. “Don’t take the chance. It’s not worth your life.”

    Oulton says he and his team are constantly finding new and different drugs and substances in pills – things they’ve never seen before.

    One machine in the lab is almost the equivalent of an MRI in a medical office, showing the structure and detail of a pill.

    “We will do what we call structural elucidation to determine that this is a different version of a fentanyl that’s got a new compound and molecule that’s been added to it,” Oulton said.

    They’ve seen “hundreds and hundreds of unique combinations,” he said.

    “We’ll see one that contains fentanyl, one with fentanyl and xylazine, one with fentanyl and caffeine, one with fentanyl and acetaminophen, and you don’t know what you’re getting.”

    Xylazine, a veterinary tranquilizer, poses a unique problem. It’s not an opioid, so even when it’s mixed with fentanyl, drugs designed to reverse an opioid overdose may not work.

    Narcan or naloxone, one of the more common overdose-reversing drugs, has become increasingly necessary as the prevalence and potency of illicit drugs increases. About 1.2 million doses of naloxone were dispensed by retail pharmacies in 2021, according to data published by the American Medical Association – nearly nine times more than were dispensed five years earlier.

    Oulton wants to be clear: The problem Isn’t with pills prescribed by your doctor and dispensed by a pharmacy – it’s the pills on the illicit market.

    Those, Matthew’s mother warns, are easy to get.

    “The first pills [Matthew] got was in high school. And it was just flipping out, floating around, and it was easy for him to get his hands on,” she said.

    Loudon’s message for parents now: Keep your eyes open.

    “Just be mindful of what your children are doing. You just just have to keep your eyes open. And even sometimes, when you keep your eyes open, you can miss some of the warning signs, but I think a parent knows their child best, so just keep talking.”

    [ad_2]

    Source link

  • Blinken under pressure to push China on role in lethal fentanyl trade when he visits Beijing | CNN Politics

    Blinken under pressure to push China on role in lethal fentanyl trade when he visits Beijing | CNN Politics

    [ad_1]



    CNN
     — 

    Members of Congress are urging Secretary of State Antony Blinken to pressure China to do more to curb the flow of fentanyl and synthetic opioids into the United States on his visit to the country which is expected to take place in the next few days.

    On Wednesday, a group of 14 Republican senators led by Marco Rubio of Florida wrote to Blinken ahead of his trip highlighting China’s role in the “fentanyl crisis” as one of many issues they wanted him to address.

    More than 100,000 Americans died of drug overdoses from July of 2021 to July of 2022 and two thirds of those deaths were fueled by synthetic opioids, primarily fentanyl, according to the CDC.

    An extremely powerful synthetic drug, fentanyl is 50 to 100 times more potent than morphine and 30 to 50 times more potent than heroin.

    The Chinese government cracked down on the manufacture and distribution of fentanyl in 2019, in a move that was hailed by the Trump administration. As a result, China it is no longer the primary source of fentanyl getting into the US. But it’s still the key source of precursor chemicals which are often shipped to Mexico and used by cartels to produce fentanyl which is brought over the border.

    “China is the leading producer of these precursor chemicals and is shipping and selling them to the two major Mexican cartels (Sinaloa and New Generation) producing fentanyl,” explained David Luckey, a senior international and defense researcher at RAND Corporation.

    “Virtually 98% of the precursor chemicals that are made used to make fentanyl are coming from China,” Democratic Rep. David Trone of Maryland told CNN. Getting China to engage on this crisis “has got to be Secretary Blinken’s number one mission when he gets there.”

    Experts and lawmakers say the production of precursor chemicals in China is a primary factor fueling the ongoing opioid crisis.

    “Synthetic opioid trafficking is an area where even a few meaningful steps from the PRC (People’s Republic of China) can play a significant role in combating this worsening epidemic and saving American lives,” Trone wrote in a letter to Blinken last month. He urged Blinken not to negotiate with Chinese officials on other topics until he has secured a commitment from Beijing to do more to stem the fentanyl crisis.

    Trone, whose nephew died of a fentanyl overdose, believes China should commit to adopting rules requiring drug companies to know who their customers are, put into place and enforce export regulations on the chemical sector, and cooperate with US agencies including the Drug Enforcement Administration and Office of National Drug Control Policy to crack down on the fentanyl trade.

    Blinken has directed his team at the State Department to work with interagency partners to do “everything possible” to address this deadly crisis which is the leading killer of Americans between the ages of 18 to 49, State Department spokesperson Ned Price said earlier this year.

    But it’s unclear what direct asks he will make of the Chinese government during his visit.

    “Though its past action has helped to counter illicit synthetic drugs, we continue to urge the PRC to take additional meaningful concrete action to curb the diversion of precursor chemicals and equipment used by criminals to manufacture fentanyl and other synthetic drugs,” Price said.

    Some lawmakers believe that Blinken should offer trade talks with China if it engages on efforts related to stemming the fentanyl crisis. Yet other congressional aides say that China will only respond to pressure and believe that the administration should consider steps including additional sanctions related to the dangerous substances – to force their engagement.

    Todd Robinson, the top State Department official for international narcotics and law enforcement affairs, said that the effective way to approach the challenge will be through “collaboration and cooperation.”

    “China has its own problems with narcotics. Mexico has problems has its problems with narcotics. Colombia also has a problem. And what we’ve been saying is, this is no longer an issue where you can solely use one or the other. Everybody’s got a problem.”

    But the need for Chinese engagement is clear: reducing the supply of precursor chemicals from China would have a “huge” impact on the crisis and would “mean a dramatic decrease” in US deaths resulting from drug overdoses, Robinson said.

    China is the largest producer of chemicals that are in everyday products such as cleaning supplies. Many Chinese companies have begun producing and selling the precursor chemicals in addition to the chemicals they have already been producing.

    Challenges to tackling the root of the problem persist when China and other countries often turn the tables on the US and blame Americans for the addiction problem which drives the demand.

    “It’s not as simple as saying, ‘China, stop producing and exporting these chemicals’. There are several sides to this issue. In response, China, for example, could counter with, ‘Americans, stop buying and using drugs,’” said Luckey.

    Many Americans with a direct connection to the crisis are watching Blinken’s trip closely.

    West Virginia – which had more than 1,300 deaths due to synthetic opioids from March of 2021 to March of 2022, according to the CDC – is an epicenter of the domestic crisis.

    Jordan Dennison lives in the state, grew up with parents who were drug addicts, and developed his own opioid addiction in his teens. A few years ago – after more than 10 overdoses – he finally got clean. The 30-year-old now works at an outreach program to get addicts into treatment.

    “Drugs led me to lose everything. Every relationship I ever had. I came to learn that what I was using was not heroine it was fentanyl. I was getting it off the street, I would go anywhere to get it,” he told CNN. “I never knew where it came from, but I always assumed it was coming from China.”

    [ad_2]

    Source link

  • First on CNN: Biden administration to strengthen Obamacare contraceptive mandate in proposed rule | CNN Politics

    First on CNN: Biden administration to strengthen Obamacare contraceptive mandate in proposed rule | CNN Politics

    [ad_1]



    CNN
     — 

    The Biden administration wants to make it easier for women to access birth control at no cost under the Affordable Care Act, reversing Trump-era rules that weakened the law’s contraceptive mandate for employer-provided health insurance plans.

    The proposed rule, unveiled Monday by the departments of Health and Human Services, Labor and Treasury, would remove an exemption to the mandate that allows employers to opt out for moral convictions. It would also create an independent pathway for individuals enrolled in plans offered by employers with religious exemptions to access contraceptive services through a willing provider without charge.

    The proposed rule would leave in place the existing religious exemption for employers with objections, as well as the optional accommodation for contraceptive coverage.

    The administration crafted the proposed rule keeping in mind the concerns of employers with religious objections and the contraceptive needs of their workers, a senior HHS official told CNN.

    “We had to really think through how to do this in the right way to satisfy both sides, but we think we found that way,” the official said, stressing that there should be no effect on religiously affiliated employers.

    Students at religiously affiliated colleges would have access to the expanded accommodation, just like workers in group health plans where the employer has claimed the exemption.

    Now that the proposed rule has been announced, the public will have the opportunity to comment during the next few months. Officials expect there to be many thousands of public comments, and it will be “many months” before the rule could be finalized.

    HHS expects the proposal would affect more than 100 employers and 125,000 workers, mainly through providing the proposed independent pathway for employees to receive no-cost contraception.

    Women using that pathway would obtain their birth control from a participating provider, who would be reimbursed by an insurer on the Affordable Care Act exchanges. The insurer, in turn, would receive a credit on the user fee it pays the government.

    “If this rule is finalized, individuals who have health plans that would otherwise be subject to the ACA preventive services requirements but have not covered contraceptive services because of a moral or religious objection, and for which the sponsoring employer or college or university has not elected the optional accommodation, would now have access,” Centers for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure said in a news release.

    How many people benefit, however, would depend on whether women and their health care providers know the independent pathway exists and whether providers and insurers are willing to set it up.

    “We’ll just have to see how widely that information is spread and in what way to providers and individuals,” said Laurie Sobel, associate director for Women’s Health Policy at the Kaiser Family Foundation, noting that the proposed rule would not require data collection to show the pathway’s takeup.

    But the Planned Parenthood Federation of America cheered the initiative.

    “Employers and universities should not be able to dictate personal health care decisions and impose their views on their employees or students,” said Alexis McGill Johnson, the group’s CEO. “The ACA mandates that health insurance plans cover all forms of birth control without out-of-pocket costs. Now, more than ever, we must protect this fundamental freedom.”

    The requirement to provide no-cost contraception is not in the Affordable Care Act itself. Instead, HHS under former President Barack Obama included it as one of the women’s preventive services that all private insurance plans must offer without charge.

    The mandate was controversial from the start, sparking lawsuits from religiously affiliated employers and closely held companies that said it violated their beliefs. Exemptions and accommodations have been available for such employers.

    The Trump administration, however, weakened the mandate. Under the rules issued in 2018, entities that have “sincerely held religious beliefs” against providing contraceptives are not required to do so. That provision also extends to organizations and small businesses that have objections “on the basis of moral conviction which is not based in any particular religious belief.”

    The rules also include an optional accommodation that lets objecting employers and private universities remove themselves from providing birth control coverage while still allowing their workers and dependents access to contraception. But the employer or university has to voluntarily elect the accommodation, which risks leaving many without access.

    The Trump administration changes were temporarily blocked after a Pennsylvania district court judge issued a nationwide injunction in 2019. But the following year, the Supreme Court ruled that the administration could expand exemptions for employers who have religious or moral objections to covering contraception.

    At the time, the National Women’s Law Center estimated that the ruling would impact about 64.3 million women in the United States with insurance coverage that included birth control and other preventive services without out-of-pocket costs.

    Employers are not required to notify HHS if they have a moral objection. The agency estimates about 18 employers have claimed that exemption and around 15 employees are affected.

    Still, if the rule is finalized, senior HHS officials say it is “plausible” there could be potential lawsuits brought by religiously affiliated employers – similar to what has been seen in the past.

    “There’s no new obligation on them to participate in any sort of process. This is simply an additional channel for employees in those employer health plans to receive access to contraceptive services,” another senior HHS official said.

    The contraceptive mandate has taken on increased importance now that the Supreme Court has overturned Roe v. Wade, allowing many states to impose severe restrictions on abortion access.

    The Biden administration in turn has focused on continuing access to birth control at no cost. The Health, Labor and Treasury department secretaries last year met with health insurers and issued guidance underscoring Obamacare’s contraceptive coverage requirements for private insurance under the Affordable Care Act.

    “Now more than ever, access to and coverage of birth control is critical as the Biden-Harris Administration works to help ensure women everywhere can get the contraception they need, when they need it, and – thanks to the ACA – with no out-of-pocket cost,” HHS Secretary Xavier Becerra said in a news release.

    This story has been updated with additional information.

    [ad_2]

    Source link

  • FTC calls on federal court to hold ‘pharma bro’ Martin Shkreli in contempt | CNN Business

    FTC calls on federal court to hold ‘pharma bro’ Martin Shkreli in contempt | CNN Business

    [ad_1]


    Washington
    CNN
     — 

    The Federal Trade Commission on Friday called for a federal court to hold “Pharma Bro” Martin Shkreli in contempt after Shkreli allegedly flouted a recent FTC investigation into his business dealings and failed to make a $64.6 million payment he owed for his prior wrongdoings.

    The FTC’s contempt motion follows what the agency described as its an unsuccessful attempt to verify whether Shkreli has violated a court order barring him from ever working in the pharmaceutical industry again.

    Brianne Murphy, an attorney for Shkreli, called the issue with the FTC a misunderstanding that “can get resolved relatively quickly once we get additional information and context to them.” Murphy added that Shkreli’s new business does not run afoul of the court order because the new company “is a software company, rather than a drug company.”

    Shkreli was released from federal prison last year after serving a shortened sentence. He was convicted of securities fraud in 2017 for mismanaging two investments funds.

    Shkreli also infamously raised prices for the life-saving medication Daraprim by 4,000% while he was head of Turing Pharmaceuticals. His conduct earned him the title of “most hated man in America” by multiple publications. More recently, he was the subject a 134-page ruling in 2022 by the US District Court for the Southern District of New York that banned him for life from participating in the pharmaceutical industry, as part of a separate FTC antitrust case against him.

    That legally binding order triggered a new investigation into Shkreli’s activities in October, when public reports indicated he had co-founded a new “Web3 drug discovery software platform” known as Druglike, Inc.

    When the FTC emailed Shkreli to get documents from him and to schedule an interview about the matter, Shkreli repeatedly missed deadlines and allegedly slow-walked his responses, according to an FTC court filing Friday.

    “Shkreli has not attempted—much less ‘diligently,’ as Second Circuit law requires—to comply with the Order in a reasonable manner,” the filing said.

    The FTC also said Shkreli had been ordered to make his multimillion-dollar payment — representing a refund of his ill-gotten Daraprim gains — by March 6, 2022. But in fact, the FTC said, “to date he has paid nothing toward the judgment, and has made no efforts to comply with this provision of the Order.”

    As far as his involvement with Druglike, the FTC added: “Shkreli’s noncompliance is also clear and unambiguous: Shkreli has not submitted a supplemental Compliance Report, provided access to relevant documents, or made himself available for an interview.”

    [ad_2]

    Source link

  • Walgreens removes online purchasing limits for children’s fever medications | CNN

    Walgreens removes online purchasing limits for children’s fever medications | CNN

    [ad_1]



    CNN
     — 

    After weeks of high demand that stretched supply, Walgreens removed its online purchasing limits for children’s pain- and fever-reducing medications on Monday morning, spokesperson Zoe Krey told CNN.

    Walgreens only had limits in place on medicines purchased online. It did not have limits on medication purchased in stores.

    “So currently, we have no purchase limits either in-store or online,” Krey said.

    The change comes after high demand for children’s pain and fever medications led some stores, including CVS and Rite Aid, to limit purchases. A brutal respiratory virus season fueled the sales of kids’ medications to treat pain and fever to 65% higher than what was typical the year before.

    CVS on Monday told CNN there is currently a two product limit on all children’s pain relief products at its stores and online. A spokesperson for the chain said the limits were in place “to ensure equitable access for all our customers,” and said CVS was working with its suppliers to ensure continued access to the items.

    CNN has also reached out to Rite Aid for comment.

    Last month, the Consumer Healthcare Products Association, which represents makers of over-the-counter medicines, said manufacturers were running 24/7 to supply more medications to stores, but there was no timeline for when supply could catch up to demand.

    Since then, flu and RSV activity have peaked in the US, according to data from the US Centers for Disease Control and Prevention. Covid-19 cases are still on the rise.

    Still, flu and other respiratory virus activity remains “high” or “very high” in about half of states, according to CDC data updated Friday, and the US continues to contend with multiple respiratory viruses that are circulating at high levels.

    [ad_2]

    Source link

  • Alabama attorney general says people who take abortion pills could be prosecuted | CNN Politics

    Alabama attorney general says people who take abortion pills could be prosecuted | CNN Politics

    [ad_1]



    CNN
     — 

    Alabama’s Republican attorney general said this week that women in the state who use prescription medication to terminate their pregnancies could be prosecuted under a chemical-endangerment law, even though Alabama’s anti-abortion law does not intend to punish women who receive abortions.

    Steve Marshall made the comments in the wake of a decision earlier this month by the US Food and Drug Administration to allow certified pharmacies to dispense the abortion medication mifepristone to people who have a prescription.

    “The Human Life Protection Act targets abortion providers, exempting women ‘upon whom an abortion is performed or attempted to be performed’ from liability under the law,” Marshall said in a statement to AL.com on Tuesday. “It does not provide an across-the-board exemption from all criminal laws, including the chemical-endangerment law—which the Alabama Supreme Court has affirmed and reaffirmed protects unborn children.”

    The chemical endangerment law was passed in 2006 amid high drug usage in Alabama with aims of protecting children from chemicals in the home, but district attorneys have successfully applied the law to protect fetuses of women who used drugs during pregnancy.

    It’s unclear if there are any pending cases against women in Alabama in the wake of the FDA’s announcement. CNN has reached out to Marshall’s office for comment.

    At least one Democrat, Alabama state Rep. Chris England, argued on Twitter that the chemical endangerment law is “extremely clear” and under it, a woman could not be prosecuted for taking a lawfully prescribed medication.

    “Any prosecutor that tries this, or threatens it, is intentionally ignoring the law,” England wrote on Thursday morning.

    Emma Roth, an attorney with Pregnancy Justice, a nonprofit that provides legal representation for women charged with crimes related to pregnancy, said on Twitter that the effect of Marshall’s comments will be to create “a culture of fear among pregnant women.”

    The comments are “extremely concerning and clearly unlawful,” Roth elaborated in a statement to CNN. “The Alabama legislature made clear its opposition to any such prosecution when it explicitly exempted patients from criminal liability under its abortion ban.”

    The chemical endangerment law says it does not require reporting controlled substances that are prescription medications “if the responsible person was the mother of the unborn child, and she was, or there is a good faith belief that she was, taking that medication pursuant to a lawful prescription.”

    Mifepristone can be used along with another medication, misoprostol, to end a pregnancy. Previously, these pills could be ordered, prescribed and dispensed only by a certified health care provider. During the Covid-19 pandemic, the FDA allowed the pills to be sent through the mail and said it would no longer enforce a rule requiring people to get the first of the two drugs in person at a clinic or hospital.

    Marshall’s comments underscore the legal uncertainty wrought by the Supreme Court’s decision last year to end the federal right to an abortion. In the wake of the Dobbs decision, several Republican-led states passed strict anti-abortion laws, while several others, including Alabama, that had passed so-called trigger laws anticipating an eventual overturn of Roe v. Wade, saw their new restrictions go into effect.

    While the anti-abortion movement seeks to prevent abortions from taking place, it has often opposed criminalizing the women who undergo the procedure.

    [ad_2]

    Source link

  • TikTok is ‘digital fentanyl,’ incoming GOP China committee chair says | CNN Business

    TikTok is ‘digital fentanyl,’ incoming GOP China committee chair says | CNN Business

    [ad_1]


    Washington
    CNN
     — 

    TikTok is an addictive drug China’s government is providing to Americans, says the incoming chairman of a new House select committee on China.

    GOP Rep. Mike Gallagher of Wisconsin told NBC’s “Meet The Press” in an interview that aired Sunday that he calls TikTok “digital fentanyl” because “it’s highly addictive and destructive and we’re seeing troubling data about the corrosive impact of constant social media use, particularly on young men and women here in America,” and also because it “effectively goes back to the Chinese Communist Party.”

    Gallagher, whom House Republican leader Kevin McCarthy has appointed to chair the new select committee in the new Congress, has said he believes the video app should be banned in the United States. (McCarthy is the apparent front-runner to become House speaker when the new session begins Tuesday, though he still does not have enough vote commitments to be elected in the floor vote.)

    TikTok, whose parent company, ByteDance, is Chinese-owned, has been banned from electronic devices managed by the US House of Representatives, according to an internal notice sent to House staff. Separately, the US government will ban TikTok from all federal devices as part of legislation included in the $1.7 trillion omnibus bill that President Joe Biden signed last week. The move comes after more than a dozen states in recent weeks have implemented their own prohibitions against TikTok on government devices.

    TikTok has previously called efforts to ban the app from government devices “a political gesture that will do nothing to advance national security interests.” TikTok declined to comment on the House restrictions.

    Gallagher says he wants to go further. As TikTok surges in popularity, he believes it needs to be reined in.

    “We have to ask whether we want the CCP to control what’s on the cusp of becoming the most powerful media company in America,” he told NBC. Gallagher supported the ban on TikTok on government devices and said the United States should “expand that ban nationally.”

    The company has been accused of censoring content that is politically sensitive to the Chinese government, including banning some accounts that posted about China’s mass detention camps in its western region of Xinjiang. The US State Department estimates that up to 2 million Uyghurs and other Muslim minorities have been detained in these camps.

    “What if they start censoring the news, right? What if they start tweaking the algorithm to determine what the CCP deems fit to print,” Gallagher warned, analogizing the situation to the KGB and Pravda buying The New York Times and other major newspapers during the height of the Cold War.

    US policymakers have cited TikTok as a potential national security risk, and critics have said ByteDance could be compelled by Chinese authorities to hand over TikTok data pertaining to US citizens or to act as a channel for malign influence operations. Security experts have said that the data could allow China to identify intelligence opportunities or to seek to influence Americans through disinformation campaigns.

    There is no evidence that that has actually occurred, though the company last month confirmed that it fired four employees who improperly accessed the TikTok user data of two journalists on the platform.

    But TikTok has hundreds of millions of downloads in the United States, and the highly influential social media platform has helped countless online creators build brands and livelihoods. As its popularity soars, TikTok may have grown too big to ban.

    Since 2020, TikTok has been negotiating with the US government on a potential deal to resolve the national security concerns and allow the app to remain available to US users. TikTok has said that the potential agreement under review covers “key concerns around corporate governance, content recommendation and moderation, and data security and access.” The company has also taken some steps to wall off US user data, organizationally and technologically, from other parts of TikTok’s business.

    But an apparent lack of progress in the talks has led some of TikTok’s critics, including in Congress and at the state level, to push for the app to be banned from government devices and potentially more broadly.

    Gallagher said on “Meet the Press” that he would be open to a sale of TikTok to an American company, but “the devil is in the details.” He continued, “I don’t think this should be a partisan issue.”

    When asked about Russia’s investment in Telegram and the Saudi investment in Twitter, Gallagher said that his “broad concern, of which both of those are part, is where we see authoritarian governments exploiting technology in order to exert total control over their citizens,” calling it “techno-totalitarian control.”

    Gallagher also called for “reciprocity,” noting that Chinese officials are allowed on apps like Twitter but Chinese citizens are not allowed access to those same apps. He said he would like to see an arrangement under which “if your government doesn’t allow your citizens access to the platform, we’re going to deny your government officials access to that same platform.”

    “The government can’t raise your kids, can’t protect your kids for you,” Gallagher said, “but there are certain sensible things we can do in order to create a healthier social media ecosystem.”

    [ad_2]

    Source link

  • Myths and facts about treating a hangover | CNN

    Myths and facts about treating a hangover | CNN

    [ad_1]

    Editor’s Note: Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information and tools designed to improve your well-being.



    CNN
     — 

    Are you celebrating the first day of 2023 with a hangover?

    If so, you might be looking for a method to ease your misery. There are certainly a lot of so-called hangover cures, some dating back centuries.

    “The ancient Greeks believed that eating cabbage could cure a hangover, and the Romans thought that a meal of fried canaries would do the trick,” said Dr. John Brick, former chief of research at the Center of Alcohol Studies, Education and Training Division at Rutgers University in New Jersey, who authored “The Doctor’s Hangover Handbook.”

    “Today, some Germans believe that a hearty breakfast of red meat and bananas cures hangovers. You might find some French drinking strong coffee with salt, or some Chinese drinking spinach tea,” he said. “Some of the more unusual hangover cures are used by some people in Puerto Rico, who rub half a lemon under their drinking arm.”

    In truth, the only cure for a hangover is time, according to the National Institute on Alcohol Abuse and Alcoholism.

    “A person must wait for the body to finish clearing the toxic byproducts of alcohol metabolism, to rehydrate, to heal irritated tissue, and to restore immune and brain activity to normal,” according to the institute. That recovery process can take up to 24 hours.

    Are there things you can do to ease your transition? Possibly, experts say, but many common hangover “cures” may make your hangover worse. Here’s how to separate fact from fiction.

    Having another drink, or the “hair of the dog that bit you,” is a well-known cure for a hangover, right? Not really, experts say.

    The reason some people believe it works is because once the calming effects of alcohol pass, the brain on a hangover is overstimulated. (It’s also the reason you wake up in the middle of the night once your body has metabolized alcohol.)

    “You’ve got this hyperexcitability in the brain after the alcohol is gone,” said Dr. Robert Swift, a professor of psychiatry and human behavior at Brown University’s Warren Alpert Medical School in Providence, Rhode Island.

    “If you look at the brain of somebody with a hangover, even though the person might feel tired, their brain is actually overexcited,” he said.

    Consuming more alcohol normalizes the brain again, “because you’re adding a sedative to your excited brain,” Swift said. “You feel better until the alcohol goes away and the cycle repeats in a way.”

    The answer is yes, depending on hangover symptoms, Brick said. If you’re a coffee drinker, skipping your morning cup of joe may lead to caffeine withdrawal on top of your hangover.

    But coffee can irritate the stomach lining, which is already inflamed by alcohol, Brick said. So if you are queasy and nauseous, coffee may only make matters worse.

    “If you have a hangover, have a quarter of a cup of coffee,” Brick suggested. “See if you feel better — it takes about 20 minutes for the caffeine to start to have some noticeable effect.

    “If coffee doesn’t make you feel better, don’t drink anymore. Obviously, that’s not the cure for your hangover.”

    Forget eating a greasy breakfast in the wee hours after a night of drinking — you’re adding insult to injury, Swift said: “Greasy food is harder to digest, so it’s probably good to avoid it.”

    Eating greasy food also doesn’t make much sense. The alcohol we drink, called ethyl alcohol or ethanol, is the byproduct of fermenting carbohydrates and starches, usually some sort of grain, grape or berry. While it may create some tasty beverages, ethanol is also a solvent, Brick said.

    “It cuts through grease in your stomach much the same way it cleans grease off oily car parts,” he said.

    Instead, experts suggest using food to prevent hangovers, by eating before you have that first drink.

    “Eating food loaded with protein and carbohydrates can significantly slow down the absorption of alcohol,” Brick said. “The slower the alcohol gets to your brain, the less rapid the ‘shock’ to your brain.”

    Alcohol dehydrates, so a headache and other hangover symptoms may be partly due to constricted blood vessels and a loss of electrolytes, essential minerals such as sodium, calcium and potassium that your body needs.

    If you’ve vomited, you’ve lost even more electrolytes, and all of this can lead to fatigue, confusion, irregular heart rate, digestive problems and more.

    Replacing lost fluids with water or a type of sports drink with extra electrolytes can help boost recovery from a hangover, Swift said.

    Taking over-the-counter pain meds can be dangerous, especially if you take too many while intoxicated, experts say. Taking an acetaminophen, such as Tylenol, can further damage your overtaxed liver, while aspirin and ibuprofen can irritate your stomach lining.

    “You should never, never take alcohol with acetaminophen or Tylenol,” Swift said. “You can actually cause liver damage from an overdose of Tylenol.”

    But aspirin, ibuprofen and naproxen are “theoretically” OK, he added.

    “Even though they tend to be anti-inflammatory in the body, they can cause inflammation in the stomach,” Swift said. “Don’t take them on an empty stomach; always take anti-inflammatories with food.”

    While most alcohol is handled by the liver, a small amount leaves the body unchanged through sweat, urine and breathing.

    Get up, do some light stretching and walking, and drink plenty of water to encourage urination, Brick said.

    “Before you go to sleep and when you wake up, drink as much water as you comfortably can handle,” he said. You can also take a multivitamin “before you hit the shower in the morning (to) replenish lost vitamins, minerals and other nutrients.”

    If you would rather have something warm and soothing, Brick suggested broth or other homemade soups.

    “These will also help to replace lost salts, including potassium and other substances,” he said, “but will not make you sober up faster or improve impairment due to intoxication or hangover.”

    Store shelves are packed with so-called hangover cures. Unfortunately, there’s no proof they work. In 2020, researchers published what they called the “world’s largest randomised double-blind placebo-controlled” trial of supplements containing vitamins, minerals, plant extracts and antioxidants and found no real improvement in hangover symptoms.

    Even if one solution works, it likely won’t fix all your symptoms, experts say.

    “The effects of alcohol and alcoholic beverages are so complicated, so complex,” Swift said, “that any solution might address one or two of the symptoms but won’t address them all.”

    What does work for a hangover? Time. It will take time for your body to release all the toxins causing your misery, experts say. And the only way to prevent a hangover is to abstain.

    [ad_2]

    Source link

  • Indian maker of cough syrup linked to Uzbekistan deaths halts production | CNN Business

    Indian maker of cough syrup linked to Uzbekistan deaths halts production | CNN Business

    [ad_1]


    New Delhi
    CNN
     — 

    The Indian maker of a cough syrup linked to at least 18 deaths in Uzbekistan has halted production after an investigation by drug regulators, India’s health minister said Friday.

    Uzbekistan’s health ministry said the cough syrup, Doc-1, manufactured by the Indian pharmaceutical company Marion Biotech, had contained ethylene glycol, a toxic solution.

    The Uzbek ministry said seven employees have been dismissed due to negligence and that all relevant documents have been given to law enforcement for an investigation. The ministry also said the cough syrup was incorrectly used by parents.

    On Friday, Indian heath minister Mansukh Mandaviya tweeted that all Marion Boitech’s manufacturing activities at their headquarters in the northern state of Uttar Pradesh had been stopped as of Thursday evening “while further investigation is ongoing,” following an inspection by India’s drug regulatory agency.

    Marion Biotech could not be immediately reached for comment.

    Hasan Harris, Marion Biotech’s legal head, told Indian news agency ANI: “We await the reports, the factory was inspected. We’ve halted production of all medicines.” As of Friday, the company’s website was not operational.

    In a statement Tuesday, Uzbekistan said the Doc-1 Max syrup was incorrectly used by parents as an anti-cold remedy on their own or on the recommendation of pharmacy sellers and this resulted in respiratory distress in children who consumed the medication.

    The Uzbek health ministry said in its statement that the deceased children had taken 2.5-5ml of the drug at home for 2-7 days, which exceeds the standard dose of the drug for children, prior to being admitted to the hospital. All children had been given the drug without a doctor’s prescription, the ministry added.

    It remains unclear how many of the children consumed the cough syrup tainted with ethylene glycol, or had been given more than the standard dosage, or both.

    The ministry said it had withdrawn all tablets and syrups of the drug from pharmacies across the country and said that 7 responsible employees have been dismissed from their positions “due to negligent and careless attitude to their duties.” It also said disciplinary measures are being applied against a number of specialists, but it did not specify who or what those measures would be.

    Ethylene glycol is commonly found in anti-freeze used in motor vehicles. If ingested, it can damage the brain, lungs, liver and kidneys, and can lead to death.

    [ad_2]

    Source link

  • Justice Department sues pharmaceutical company for allegedly failing to report suspicious opioid sales | CNN Politics

    Justice Department sues pharmaceutical company for allegedly failing to report suspicious opioid sales | CNN Politics

    [ad_1]


    Washington
    CNN
     — 

    The Justice Department on Thursday alleged that the AmerisourceBergen Corporation, one of the country’s largest pharmaceutical distributors, and two of its subsidiaries failed to report hundreds of thousands of suspicious prescription opioid orders to pharmacies across the country.

    The lawsuit, which spans several states, alleges that AmerisourceBergen disregarded its legal obligation to report orders of controlled substances to the Drug Enforcement Agency for nearly a decade. The company ignored “red flags” that pharmacies in West Virginia, New Jersey, Colorado and Florida were diverting opioids into illegal drug markets, the suit says.

    “The Department of Justice is committed to holding accountable those who fueled the opioid crisis by flouting the law,” Associate Attorney General Vanita Gupta said in a statement Thursday.

    “Companies distributing opioids are required to report suspicious orders to federal law enforcement. Our complaint alleges that AmerisourceBergen – which sold billions of units of prescription opioids over the past decade – repeatedly failed to comply with that requirement,” she added.

    If AmerisourceBergen is found liable at trial, the company faces billions of dollars in financial penalties, the Justice Department said.

    Lauren Esposito, a spokesperson for AmerisourceBergen, countered on Thursday in a statement that said the Justice Department’s complaint rested on “five pharmacies that were cherry picked out of the tens of thousands of pharmacies that use AmerisourceBergen as their wholesale distributor, while ignoring the absence of action from former administrators at the Drug Enforcement Administration – the DOJ’s own agency.”

    She added: “With the vast quantity of information that AmerisourceBergen shared directly with the DEA with regards to these five pharmacies, the DEA still did not feel the need to take swift action itself – in fact, AmerisourceBergen terminated relationships with four of them before DEA ever took any enforcement action while two of the five pharmacies maintain their DEA controlled substance registration to this day.”

    Yet AmerisourceBergen was allegedly aware that in two of the pharmacies, drugs it distributed were likely being sold in parking lots for cash, the Justice Department said. In another pharmacy, the company was allegedly warned that patients likely suffering from addiction were receiving opioids, including some people who later died of a drug overdose.

    The Justice Department also noted in its lawsuit that AmerisourceBergen’s reporting systems for suspicious opioid orders were deeply inadequate, and that the company intentionally changed its reporting systems to reduce the number of orders flagged as suspicious amid the opioid epidemic.

    Even when orders were flagged as suspicious, AmerisourceBergen often didn’t report those orders to the DEA, according to the complaint.

    Opioids are involved in the vast majority of drug overdose deaths, though synthetic opioids – particularly fentanyl – have played an outsized role. Synthetic opioids – excluding methadone – were involved in more than 72,000 overdose deaths in 2021, about two-thirds of all overdose deaths that year and more than triple the number from five years earlier.

    [ad_2]

    Source link

  • House investigation says FDA approval process of Alzheimer’s drug was ‘rife with irregularities’ | CNN

    House investigation says FDA approval process of Alzheimer’s drug was ‘rife with irregularities’ | CNN

    [ad_1]



    CNN
     — 

    A congressional investigation found that the US Food and Drug Administration’s “atypical collaboration” to approve a high-priced Alzheimer’s drug was “rife with irregularities.”

    The report, released Thursday, was the result of an 18-month investigation by two House committees. It is sharply critical of Biogen, maker of the medication Aduhelm.

    The report says Biogen set an “unjustifiably high price” for Aduhelm to “make history” for the company, and thought of the drug as an “unprecedented financial opportunity.” Biogen priced Aduhelm at $56,000 per year, even though its actual effects on a broad patient population were unknown.

    More than 6.5 million people in the US live with Alzheimer’s, and that number is expected to grow to 13.8 million by 2060, according to the Alzheimer’s Association. The disease is the sixth leading cause of death in the United States. There is no cure, and effective treatments are extremely limited. Before Aduhelm’s approval in June 2021, the FDA had not approved a novel therapy for the condition since 2003.

    The investigation found that Biogen planned an aggressive marketing campaign to launch the drug, intending to spend more than $3.3 billion on sales and marketing between 2020 and 2024 – more than 2½ times what it spent to develop Aduhelm.

    Dementia, including Alzheimer’s, is one of the “costliest conditions to society,” according to the Alzheimer’s Association. In 2022 alone, Alzheimer’s and other dementias cost the US $321 billion, including $206 billion in Medicaid and Medicare payments, the association says.

    Aduhelm’s cost to patients and to Medicare would be significant, the new report says. It was one of the key factors behind a big increase in Medicare premiums in 2022, according to the Centers for Medicare and Medicaid Services.

    In anticipation of “pushback” from providers and payers, the report says, Biogen also prepared a narrative to sell the value of the drug.

    The Committee on Oversight and Reform and the Committee on Energy and Commerce found that the collaboration between the FDA and Biogen in the approval process of the drug “exceeded the norm in some respects.”

    Biogen had initially discontinued Aduhelm’s clinical trials in March 2019 after an independent committee found that it probably would not slow the cognitive and functional impairment – the decline in memory, language and judgment – that comes with Alzheimer’s. But in June 2019, the FDA and Biogen started a “working group” to see whether the effort could be saved.

    The investigation found that the FDA and Biogen engaged in at least 115 meetings, calls and substantive email discussions from July 2019 to July 2020, including 40 meetings to guide Aduhelm’s potential approval. There may have been even more meetings, but the committees say the FDA failed to follow its own documentation protocol.

    The agency then collaborated with Biogen to draft a document used to brief an independent advisory committee that met in November 2020. The trial results were mixed, with only one showing a small benefit to patients.

    At that meeting, none of the committee’s members voted to say that the studies presented strong evidence that the drug was effective at treating Alzheimer’s.

    The meeting was unusual, according to one former FDA adviser who had sat on the committee for several years. Dr. Aaron Kesselheim told CNN in 2021 that the relationship between the FDA and the company was out of the ordinary.

    “There was a strange dynamic compared to the other advisory committee meetings I’ve attended,” the professor at Harvard Medical School said. “Usually, there’s some distance between the FDA and the company, but on this one, the company and the FDA were fully in line with each other in support of the drug.”

    When the FDA approved the drug, Kesselheim and two other members of the advisory committee resigned in protest. He later labeled it “probably the worst drug approval decision in recent US history.”

    The FDA often follows the independent committee’s recommendations, but in this case, it changed course and used its accelerated approval pathway, which sets a different standard of proof that a treatment could work.

    The committee members said senior FDA leadership told them that the shift in how the drug would be approved came after an FDA expert council meeting in April 2021 provided “unfavorable feedback” for the traditional approval process, according to the new report.

    The FDA also approved the drug for “people with Alzheimer’s disease,” a far broader population than was studied in Biogen’s clinical trials.

    Internal documents from the company said that Biogen accepted this broader indication “despite internal reservations about the lack of evidence of clinical benefit for patients at disease stages outside of the clinical trials and an unknown safety profile,” the report says. Leaders expressed concern that the company could lose credibility, and it developed a communications strategy to deal with the “anticipated fallout,” the report says.

    The committees recommended that the FDA document all of its meetings with drug sponsors, establish a protocol for briefing documents and advisory committees, and update its guidance for how Alzheimer’s drugs are developed and reviewed.

    The committees also recommended that companies clearly communicate safety and efficacy concerns to the FDA and consider the value assessments made by outside experts when setting drug prices.

    “The American people rely on FDA for assurance on the safety and efficacy of the medications they take. The number of patients and families impacted by Alzheimer’s disease will continue to increase, and it is crucial that FDA and drug companies adhere to established procedures and conduct themselves with the transparency necessary to earn public trust,” the report says.

    The FDA said in a statement that its “decision to approve Aduhelm was based on our scientific evaluation of the data contained in the application, which is described in the approval materials.”

    The agency says it is reviewing the committees’ findings and recommendations and says its own review found that the interactions with Biogen were appropriate.

    “It is the agency’s job to frequently interact with companies in order to ensure that we have adequate information to inform our regulatory decision-making. We will continue to do so, as it is in the best interest of patients. That said, the agency has already started implementing changes consistent with the Committee’s recommendations.”

    Biogen said in a statement Thursday that it has been working “cooperatively” with the investigation.

    “Biogen has been committed to researching and developing treatments for Alzheimer’s disease for more than a decade. We have been focused relentlessly on innovation to address this global health challenge, and have adapted to both successes and setbacks,” it said. “Biogen stands by the integrity of the actions we have taken.”

    [ad_2]

    Source link

  • Beijing to distribute Pfizer antiviral drug as Covid wave strains health system | CNN

    Beijing to distribute Pfizer antiviral drug as Covid wave strains health system | CNN

    [ad_1]


    Beijing
    CNN
     — 

    Beijing will begin distributing Pfizer’s Covid-19 drug Paxlovid to the city’s community health centers in the coming days, state media reported Monday.

    The report comes as the city grapples with an unprecedented wave of infections that has severely strained its hospitals and emptied pharmacy shelves.

    The state-run China News Service reported Monday that after receiving training, community doctors will administer the medicine to Covid-19 patients and give instructions on how to use them.

    “We have received the notice from officials, but it is not clear when the drugs will arrive,” it cited a worker at a local community health center in Beijing’s Xicheng district as saying.

    Paxlovid remains the only foreign medicine to treat Covid that has been approved by China’s regulator for nationwide use, but access is extremely difficult to come by. When a Chinese healthcare platform offered the antiviral drug earlier this month, it sold out within hours.

    Azvudine, an oral medicine developed by China’s Genuine Biotech, has also been approved.

    After nearly three years of lockdowns, quarantines and mass testing, China abruptly abandoned its zero-Covid policy this month following nationwide protests over its heavy economic and social toll.

    The sudden lifting of restrictions sparked panic buying of fever and cold medicines, leading to widespread shortages, both at pharmacies and on online shopping platforms. Long lines have become routine outside fever clinics and hospital wards overflowing with patients in the capital Beijing and elsewhere in the country.

    An emergency room doctor in Beijing told the state-run People’s Daily on Thursday that four doctors on his shift did not have time to eat or drink. “We have been seeing patients nonstop,” he said.

    Another emergency room doctor told the newspaper he had been working despite having developed fever symptoms. “The number of patients is high, and with fewer medical staff, the pressure is multiplied,” said the doctor.

    In a sign of the strain on Beijing’s medical system, hundreds of health professionals from across China have traveled to the city to assist medical centers.

    As the capital, Beijing has some of the best medical resources in the country. However, the abrupt zero-Covid u-turn has left people and health facilities ill-prepared to deal with a surge in infections.

    China’s official Covid case count has become meaningless after it rolled back mass testing and allowed residents to use antigen tests and isolate at home. It has stopped reporting asymptomatic cases, conceding it was no longer possible to track the actual number of infections.

    According to an internal estimate from the National Health Commission, almost 250 million people in China have caught Covid in the first 20 days of December – accounting for roughly 18% of the country’s population.

    Experts have warned that as people in big cities return to their hometowns for the Lunar New Year next month, the virus could sweep through China’s vast rural areas, where vaccination rates are lower and medical resources are severely lacking.

    [ad_2]

    Source link

  • Why people in China are panic buying canned yellow peaches as Covid surges | CNN Business

    Why people in China are panic buying canned yellow peaches as Covid surges | CNN Business

    [ad_1]


    Hong Kong
    CNN
     — 

    An unprecedented wave of Covid cases in China has sparked panic buying of fever medicines, pain killers, and even home remedies such as canned peaches, leading to shortages online and in stores.

    Authorities said Wednesday they had detected 2,249 symptomatic Covid-19 cases nationally through nucleic acid testing, 20% of which were detected in the capital Beijing. CNN reporting from the city indicates the case count in the Chinese capital could be much higher than recorded.

    Demand for fever and cold medicines, such as Tylenol and Advil, is surging nationally as people rush to stockpile drugs amid fears they may contract the virus.

    Canned yellow peaches, considered a particularly nutritious delicacy in many parts of China, have been snapped up by people looking for ways to fight Covid. The product is currently sold out on many online shops.

    Its sudden surge in popularity prompted Dalian Leasun Food, one of the country’s largest canned food manufacturers, to clarify in a Weibo post that canned yellow peaches don’t have any medicinal effect.

    “Canned yellow peaches ≠ medicines!” the company said in the post published Friday. “There is enough supply, so there is no need to panic. There is no rush to buy.”

    The People’s Daily, the mouthpiece of the Communist Party, also tried to set the record straight. It published a long Weibo post on Sunday urging the public not to stockpile the peaches, calling them “useless in alleviating symptoms of illness.”

    Authorities also pleaded with the public not to stockpile medical supplies. On Monday, the Beijing city government warned residents that it was facing “great pressure” to meet demand for drug and medical services because of panic buying and an influx of patients at clinics.

    It urged the public not to hoard drugs or call emergency services if they have no symptoms.

    The rising demand and shortage of supply of Covid remedies have fueled bets on drugmakers.

    Shares of Hong Kong-listed Xinhua Pharmaceutical, China’s largest manufacturer of ibuprofen, have gained 60% in the past five days. The stock has so far jumped by 147% in the first two weeks of this month.

    “Our company’s production lines are operating at full capacity, and we are working overtime to produce urgently needed medicines, such as ibuprofen tablets,” Xinhua Pharmaceutical said Monday.

    Ibuprofen is an anti-inflammatory drug used to treat pain and fever. It is also known as Advil, Brufen, or Fenbid.

    The drug shortage has spread from mainland China to Hong Kong, a special administrative region which has a separate system of local government. On Sunday, the city’s health chief urged the public to refrain from panic buying cold medicines they do not need and urged residents “not to overact.”

    In some Hong Kong drugstores, fever drugs such as Panadol, the local brand name for Tylenol, have sold out. Most of the buyers were sending the medicines to their families and friends in the mainland, sales representatives told CNN.

    Shares of Shenzhen-listed Guizhou Bailing Group Pharmaceuticals, known for making cough syrup, have gained 21% this week and risen 51% so far this month. Yiling Pharmaceutical, the sole producer of Lianhua Qingwen, a traditional Chinese medicine recommended by the government for treating Covid, has also jumped more than 30% in the past month.

    Even providers of funeral services and burial plots have gotten a huge boost. Shares in Hong Kong-traded Fu Shou Yuan International, China’s largest burial service company, have soared more than 50% since last month.

    There is “strong pent-up demand for burial plots” in 2023, analysts from Citi Group said in a recent research report, adding that they’ve noticed increasing investor interest in the sector.

    They cited the existence of hundreds of thousands of cremated remains, which are being temporarily stored in government facilities awaiting burial. Lockdowns across much of the country have halted funeral services, they said.

    [ad_2]

    Source link

  • As China moves away from zero-Covid, health experts warn of dark days ahead | CNN

    As China moves away from zero-Covid, health experts warn of dark days ahead | CNN

    [ad_1]

    Editor’s Note: Editor’s Note: A version of this story appeared in CNN’s Meanwhile in China newsletter, a three-times-a-week update exploring what you need to know about the country’s rise and how it impacts the world. Sign up here.


    Hong Kong
    CNN
     — 

    China’s zero-Covid policy, which stalled the world’s second-largest economy and sparked a wave of unprecedented protests, is now being dismantled as Beijing on Wednesday released sweeping revisions to its draconian measures that ultimately failed to bring the virus to heel.

    The new guidelines keep some restrictions in place but largely scrap the health code system that required people to show negative Covid-19 tests for daily activities and roll back mass testing. They also allow some Covid-19 cases and close contacts to skip centralized quarantine.

    They come after a number of cities in recent days started to lift some of the harsh controls that dictated – and heavily restricted – daily life for nearly three years in China.

    But while the changes mark a significant shift – and bring relief for many in the public who’ve grown increasingly frustrated with the high costs and demands of zero-Covid – another reality is also clear: China is underprepared for the surge in cases it could now see.

    Experts say though much is still unknown about how the next weeks and months will progress, China has fallen short on preparations like bolstering the elderly vaccination rate, upping surge and intensive care capacity in hospitals, and stockpiling antiviral medications.

    While the Omicron variant is milder than previous strains and China’s overall vaccination rate is high, even a small number of severe cases among vulnerable and under-vaccinated groups like the elderly could overwhelm hospitals if infections spike across the country of 1.4 billion, experts say.

    “This is a looming crisis – the timing is really bad … China now has to relax much of its measures during the winter (overlapping with flu season), so that was not as planned,” said Xi Chen, an associate professor at the Yale School of Public Health in the United States, pointing to what was likely an acceleration in China’s transition, triggered by public discontent.

    The guidelines released Wednesday open up a new chapter in the country’s epidemic control, three years after the first cases of Covid-19 were detected in central China’s Wuhan and following protests against the zero-Covid policy across the country starting late last month.

    Where China once controlled cases by requiring testing and clear health codes for entry into a number of public places and for domestic travel, those codes will no longer be checked except for in a handful of locations like medical institutions and schools. Mass testing will now be rolled back for everyone except for those in high-risk areas and high-risk positions. People who test positive for Covid-19 but have mild or asymptomatic cases and meet certain conditions can quarantine at home, instead of being forced to go to centralized quarantine centers, as can close contacts.

    Locations classified by authorities as “high risk” can still be locked down, but these lockdowns must now be more limited and precise, according to the new guidelines, which were circulated by China’s state media.

    The changes mark a swift about-face, following mounting public discontent, economic costs and record case numbers in recent weeks. They come after a top official last week first signaled the country could move away from the zero-Covid policy it had long poured significant resources into – though another official on Wednesday said the measures were a “proactive optimization,” not “reactive” when asked in a press briefing.

    “China has pursued this policy for so long, they’re now between a rock and a hard place,” said William Schaffner, a professor of infectious diseases at the Vanderbilt University Medical Center in the US. “They don’t have good options in either direction anymore. They had really hoped that this epidemic globally would run its course, and they could survive without impact. And that hasn’t happened.”

    As restrictions are relaxed, and the virus spreads across the country, China is “going to have to go through a period of pain in terms of illness, serious illness, deaths and stress on the health care system” as was seen elsewhere in the world earlier in the pandemic, he added.

    Since the global vaccination campaign and the emergence of the Omicron variant, health experts have questioned China’s adherence to zero-Covid and pointed out the unsustainability of the strategy, which tried to use mass testing and surveillance, lockdowns and quarantines to stop a highly contagious virus.

    But as some restrictions are lifted, in what appears to be a haphazard transition following years of focus on meticulously controlling the virus, experts say change may be coming before China has made the preparations its health officials have admitted are needed.

    “An uncontrolled epidemic (one which only peaks when the virus starts running out of people to infect) … will pose serious challenges to the health care system, not only in terms of managing the small fraction of Covid cases that are severe, but also in the ‘collateral damage’ to people with other health conditions who have delayed care as a consequence,” said Ben Cowling, a professor of epidemiology at the University of Hong Kong.

    But even with easing restrictions, Cowling said, it was “difficult to predict” how quickly infections will spread though China, because there are still some measures in place and some people will change their behavior – such as staying at home more often.

    “And I wouldn’t rule out the possibility that stricter measures are reintroduced to combat rising cases,” he said.

    Experts agree that allowing the virus to spread nationally would be a significant shift for a country that up until this point has officially reported 5,235 Covid-19 deaths since early 2020 – a comparatively low figure globally that has been a point of pride in China, where state media until recently trumpeted the dangers of the virus to the public.

    Modeling from researchers at Shanghai’s Fudan University published in the journal Nature Medicine in May projected that more than 1.5 million Chinese could die within six months if Covid-19 restrictions were lifted and there was no access to antiviral drugs, which have been approved in China.

    However, death rates could fall to around the levels of seasonal flu, if almost all elderly people were vaccinated and antiviral medications were broadly used, the authors said.

    Last month, China released a list of measures to bolster health systems against Covid-19, which included directives to increase vaccination in the elderly, stockpile antiviral treatments and medical equipment, and expand critical care capacity – efforts that experts say take time and are best accomplished prior to an outbreak.

    “(Is China prepared?) If you look at surge capacity three years on and the stockpiling of effective antivirals – no. If you talk about the triage procedures – they are not strictly enforced – and if you talk about the vaccination rate for the elderly, especially those aged 80 and older, it is also overall no,” said Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations in New York.

    Chinese authorities, he added, would likely be closely assessing outcomes like the death rate to decide policy steps going forward.

    Citizens wearing masks board a subway train on Monday in Henan province's Zhengzhou, where negative Covid-19 test results are no longer required for riding public transport.

    The US has at least 25 critical care beds per 100,000 people, according to the Organization for Economic Co-operation and Development – by contrast, China has fewer than four for the same number, health authorities there said last month.

    The system also provides limited primary care, which could drive even moderately sick people to hospitals as opposed to calling a family doctor – putting more strain on hospitals, according to Yale’s Chen.

    Meanwhile, weak medical infrastructure in rural areas could foster crises there, especially as testing is reduced and younger people living in cities return to rural hometowns to visit elderly family members over the Lunar New Year next month, he said.

    While China’s overall vaccination rate is high, its elderly are also less protected than in some other parts of the world, where the oldest and most vulnerable to dying from Covid-19 were prioritized for vaccination. Some countries have already rolled out fourth or fifth doses for at-risk groups.

    By China’s accounting, more than 86% of China’s population over 60 are fully vaccinated, according to China’s National Health Commission, and booster rates are lower, with more than 45 million of the fully vaccinated elderly yet to receive an additional shot. Around 25 million elderly who have not received any shot, according to a comparison of official population figures and November 28 vaccination data.

    For the most at-risk over 80 age group, around two-thirds were fully vaccinated by China’s standards, but only 40% had received booster shots as of November 11, according to state media.

    But while China refers to third doses for its widely used inactivated vaccines as booster shots, a World Health Organization vaccine advisory group last year recommended that elderly people taking those vaccines receive three doses in their initial course to ensure sufficient protection.

    The inactivated vaccines used in China have been found to elicit lower levels of antibody response as compared to others used overseas, and many countries using the doses have paired them with more protective mRNA vaccines, which China has not approved for use.

    Cowling said evidence from Hong Kong’s outbreak, however, showed China’s inactivated vaccines worked well to prevent severe disease, but it was critical that the elderly receive three doses in the initial course, as recommended by the World Health Organization. They should then use a fourth dose on top of that to keep immunity high, he added.

    Top health officials on November 28 announced a new plan to bolster elderly vaccination rates, but such measures will take time, as will other preparations for a surge.

    Minimizing the worst outcomes in a transition out of zero-Covid depends on that preparation, according to Cowling. From that perspective, he said, “it doesn’t look like it would be a good time to relax the policies.”

    [ad_2]

    Source link

  • Early research suggests promising use of AI to predict risk of heart attack or stroke using a single chest X-ray | CNN

    Early research suggests promising use of AI to predict risk of heart attack or stroke using a single chest X-ray | CNN

    [ad_1]



    CNN
     — 

    Early research suggests a promising use of artificial intelligence to predict the 10-year risk of death from a heart attack or stroke from a single chest X-ray.

    The preliminary findings were presented Tuesday at the annual meeting of the Radiological Society of North America. The research is in the final draft stages and has not been submitted for publication in a medical journal.

    Researchers used nearly 150,000 chest X-rays to train an artificial intelligence program to identify patterns in the images associated with risk from major cardiovascular disease events. They tested the program on a separate group of about 11,000 people and found “significant association” between the risk level predicted by the AI and the actual occurrence of a major cardiovascular disease event.

    The clinical standard for analyzing risk from cardiovascular disease is the atherosclerotic cardiovascular disease (ASCVD) risk score, a calculator that weights various patient data points that have been found to have a high association with adverse cardiovascular events, including age, blood pressure and history of smoking.

    Statin medication is recommended for people with a 10-year risk of 7.5% or higher. The AI model uses the same risk thresholds as the established risk calculator, and early findings suggest that it works just as well.

    “We’ve long recognized that X-rays capture information beyond traditional diagnostic findings, but we haven’t used this data because we haven’t had robust, reliable methods,” said Dr. Jakob Weiss, the lead researcher and a radiologist affiliated with Massachusetts General Hospital and the AI in Medicine program at Harvard Medical School’s Brigham and Women’s Hospital.

    Sometimes, the AI findings align with a traditional radiology reading, but other times, it picks up on things that may have been missed, he said.

    “Part of it is anatomical alterations that we would also pick up with our naked eye and that make physiological sense. Let’s say there’s increased blood pressure or cardiac failure – these are findings that we can pick up in a normal chest radiograph as well. But I think a lot of the information captured or extracted is somewhere embedded in the scan, but we can’t make sense of it as traditionally trained radiologists as of now,” Weiss said.

    “It has this black box character to it,” he said, which can sometimes make it hard to communicate risk to patients without an explanation to pinpoint.

    Dr. Donald Lloyd-Jones, chair of preventive medicine at Northwestern University’s Feinberg School of Medicine and former president of the American Heart Association, was co-chair of the risk assessment panel when the ASCVD risk calculator was created in 2013 and a key player in 2018 when the guidelines were updated to emphasize the relationship between the risk score and personal medical history.

    He was not involved in the new AI research but says it’s important to keep the field moving forward.

    “This is exactly the kind of application that artificial intelligence is best for,” he said. “So we need to continue to do things like this to really understand if we can find, particularly, patients who would otherwise slip through the cracks. I think that’s where it may be most useful.”

    But collecting all of the patient data points that go into the established risk calculator is still critical – because they’re actionable. And whether risk is calculated using a statistical formula or an AI model, the most successful outcomes will still require personalized patient assessments.

    “We don’t cure smoking by a chest X-ray. We actually need to work with the patient to find ways to get them to stop smoking,” Lloyd-Jones said. “The risk calculator is one part of risk assessment, but it’s not the only part. It’s a process that involves both the patient and the doctor in a discussion about what is the patient’s risk and how much we think a statin would help them.”

    For their research, Weiss and co-authors trained the AI using chest X-rays from participants in the National Cancer Institute’s Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. It was tested on people who had a routine outpatient chest X-ray at Mass General Brigham and were potentially eligible for statin therapy, with an average age of 60.

    Additional research, including a controlled randomized trial, is necessary to validate the deep learning model.

    [ad_2]

    Source link

  • Don’t bother with dietary supplements for heart health, study says | CNN

    Don’t bother with dietary supplements for heart health, study says | CNN

    [ad_1]



    CNN
     — 

    Six supplements that people commonly take for heart health don’t help lower “bad” cholesterol or improve cardiovascular health, according to a study published Sunday, but statins did.

    Some people believe that common dietary supplements – fish oil, garlic, cinnamon, turmeric, plant sterols and red yeast rice – will lower their “bad” cholesterol. “Bad” cholesterol, known in the medical community as low-density lipoproteins or LDL, can cause the buildup of fatty deposits in the arteries. The fatty deposits can block the flow of oxygen and blood that the heart needs to work and the blockage can lead to a heart attack or stroke.

    For this study, which was presented at the American Heart Association’s Scientific Sessions 2022 and simultaneously published in the Journal of the American College of Cardiology, researchers compared the impact of these particular supplements to the impact of a low dose of a statin – a cholesterol-lowering medication – or a placebo, which does nothing.

    Researchers made this comparison in a randomized, single-blind clinical trial that involved 190 adults with no prior history of cardiovascular disease. Study participants were ages 40 to 75, and different groups got a low-dose statin called rosuvastatin, a placebo, fish oil, cinnamon, garlic, turmeric, plant sterols or red yeast rice for 28 days.

    The statin had the greatest impact and significantly lowered LDL compared with the supplements and placebo.

    The average LDL reduction after 28 days on a statin was nearly 40%. The statin also had the added benefit on total cholesterol, which dropped on average by 24%, and on blood triglycerides, which dropped 19%.

    None of the people who took the supplements saw any significant decrease in LDL cholesterol, total cholesterol or blood triglycerides, and their results were similar to those of people who took a placebo. While there were similar adverse events in all the groups, there were a numerically higher number of problems among those who took the plant sterols or red yeast rice.

    “We designed this study because many of us have had the same experience of trying to recommend evidence-based therapies that reduce cardiovascular risks to patients and then having them say ‘no thanks, I’ll just try this supplement,’ ” said study co-author Dr. Karol Watson, professor of medicine/cardiology and co-director, UCLA Program in Preventive Cardiology. “We wanted to design a very rigid, randomized, controlled trial study to prove what we already knew and show it in a rigorous way.”

    Dr. Steven Nissen, a cardiologist and researcher at the Cleveland Clinic and a co-author on the study, said that patients often don’t know that dietary supplements aren’t tested in clinical trials. He calls these supplements “21st century snake oil.”

    In the United States, the Dietary Supplement and Health Education Act of 1994 sharply limited the US Food and Drug Administration’s ability to regulate supplements. Unlike pharmaceutical products that have to be proven safe and effective for their intended use before a company can market them, the FDA doesn’t have to approve dietary supplements before they can be sold. It is only after they are on the market and are proven to be unsafe that the FDA can step in to regulate them.

    “Patients believe studies have been done and that they are as effective as statins and can save them because they’re natural, but natural doesn’t mean safe and it doesn’t mean they’re effective,” Nissen said.

    The study was funded via an unrestricted grant from AstraZeneca, which makes rosuvastatin. The company did not have any input on the methodology, data analysis and discussion of the clinical implications, according to the study.

    The researchers acknowledged some limitations, including the study’s small sample size, and that its 28-study period might not capture the effect of supplements when used for a longer duration.

    In a statement on Sunday, the Council for Responsible Nutrition, a trade association for the dietary supplement industry, said “supplements are not intended to replace medications or other medical treatments.”

    “Dietary supplements are not intended to be quick fixes and their effects may not be revealed during the course of a study that only spans four weeks,” Andrea Wong, the group’s senior vice president for scientific and regulatory affairs, said in a statement.

    Dr. James Cireddu, an invasive cardiologist and medical director of University Hospitals Harrington Heart & Vascular Institute at University Hospitals Bedford Medical Center, said the work is going to be helpful.

    “They did a nice job collecting data and looking at the outcomes,” said Cireddu, who did not work on the study. “It will probably resonate with patients. I get asked about supplements all the time. I think this does a nice job of providing evidence.”

    Dr. Amit Khera, chair of the AHA Scientific Sessions programming committee, did not work on the research, but said he thought this was an important study to include in the presentations this year.

    “I take care of patients every day with these exact questions. Patients always ask about the supplements in lieu of or in addition to statins,” said Khera, who is a professor and director of preventive cardiology at UT Southwestern Medical Center. “I think if you have high quality evidence and a well done study it is really critical to help inform patients about the value, or in this case the lack of value, for some of these supplements for cholesterol lowering.”

    Statins have been around for more than 30 years and they’ve been studied in over 170,000 people, he said. Consistently, studies show that statins lower risk.

    “The good news, we know statins work,” Khera said. “That does not mean they’re perfect. That doesn’t mean everyone needs one, but for those at higher risk, we know they work and that’s well proven. If you’re going to do something different you have to make sure it works.”

    With supplements, he said he often sees misinformation online.

    “I think that people are always looking for something ‘natural’ but you know there’s a lot of issues with that terminology and most important we should ask do they work? That’s what this study does,” Khera adds. “It’s important to ask, are you taking something that is proven, and if you’re doing that and it’s not, is that in lieu of proven treatment. It’s a real concern.”

    [ad_2]

    Source link